Zobrazeno 1 - 10
of 143
pro vyhledávání: '"Anti-EGFR Monoclonal Antibody"'
Autor:
Kozo Kataoka, Takeshi Yamada, Manabu Shiozawa, Naoto Takase, Kazuma Ito, Kentaro Yamazaki, Jun Watanabe, Toshihiro Kudo, Takeshi Suto, Toshihiko Matsumoto, Kohei Murata, Yusuke Suwa, Shogen Boku, Hisateru Yasui, Nobuhisa Matsuhashi, Atsuyuki Maeda, Kiichi Sugimoto, Yusuke Matsumoto, Mitsuru Yokota, Johannes Fredebohm, Keita Mori, Masataka Ikeda
Publikováno v:
Journal of the Anus, Rectum and Colon, Vol 8, Iss 2, Pp 132-136 (2024)
Background: Spatial and temporal heterogeneities of RAS and other molecular genes should be considered in the treatment of metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs); acq
Externí odkaz:
https://doaj.org/article/3c42bc614e4e45ca97f85e629c86cea8
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-27 (2023)
Abstract Background RAS mutations affect prognosis in patients with metastatic colorectal cancer (mCRC) and have been identified as strong negative predictive markers for anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) thera
Externí odkaz:
https://doaj.org/article/97cc2c35ef014513b1e5fa3aa849f062
Publikováno v:
Zhongguo aizheng zazhi, Vol 33, Iss 1, Pp 81-94 (2023)
Squamous cell carcinoma of the head and neck (SCCHN) is the most common head and neck tumor. Patients are generally diagnosed with advanced stage attributed to no clinically evident symptom at the early stage. For locally advanced SCCHN, cisplatin-ba
Externí odkaz:
https://doaj.org/article/b3e43e9a7d01460981fd18b771b6d5c6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cell Communication and Signaling, Vol 20, Iss 1, Pp 1-19 (2022)
Abstract Anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibodies (mAbs) are of great significance for RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients. However, the generation of primary and secondary resistance to anti-
Externí odkaz:
https://doaj.org/article/3a1139c3183b4809bcd6acc28ae04267
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BRAF non-V600 mutations are a distinct molecular subset of colorectal cancer (CRC) that has little to no clinical similarity to the BRAF V600 mutations. It is generally considered that the BRAF non-V600 mutations correlate with better survival of CRC
Externí odkaz:
https://doaj.org/article/568856c6d45f4f8db4326bd58ac360f8
Autor:
Qing D, Wu Y, Liu X, Jiang H, Zhu C, Liu P, Dang J, Li X, Chen Z, Long X, Pang Q, Peng L, Deng S, Gu J, Zhao R, Chen C, Lu H
Publikováno v:
Cancer Management and Research, Vol Volume 12, Pp 12309-12317 (2020)
Defeng Qing,1,* Yuying Wu,2,* Xu Liu,1,* Hailan Jiang,1,* Chaohua Zhu,1,* Pei Liu,3 Junming Dang,4 Xianglong Li,1 Zhaohong Chen,1 Xianfeng Long,1 Qiang Pang,1 Luxing Peng,1 Shan Deng,1 Junzhao Gu,1 Renfeng Zhao,2 Changyi Chen,2 Heming Lu1 1Department
Externí odkaz:
https://doaj.org/article/742fae9edfd143e688594f70c10b8eaf
Autor:
Qunli Xiong, Zhu Zeng, Yang Yang, Ya Wang, Yongfeng Xu, Ying Zhou, Jinlu Liu, Zhiwei Zhang, Meng Qiu, Qing Zhu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundClose to one third of colorectal cancer (CRC) patients are diagnosed with metastatic CRC (mCRC). Patients with wild-type RAS and BRAF usually receive anti-EGFR monoclonal antibody therapy containing cetuximab. Overall, 30–50% of mCRC pati
Externí odkaz:
https://doaj.org/article/5f0e8a615d214e049c3377f6b36c00e7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tian Fang, Tingting Liang, Yizhuo Wang, Haitao Wu, Shuhan Liu, Linying Xie, Zhihao Zhang, Jiaying Liang, Cheng Yao, Yehui Tan, Chang Wang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Mutations in KRAS (codon 12/13), NRAS, BRAFV600E, and amplification of ERBB2 and MET account for 70–80% of anti-epidermal growth factor receptor (EGFR) monoclonal antibody primary resistance. However, the list of anti-EGFR monoclonal antibody prima
Externí odkaz:
https://doaj.org/article/641d4f9bb7764406b13f2d1505420918